Core Insights - Tongrentang Technology has made significant progress in the capacity layout of liquid preparations, with the new oral liquid production line expected to submit GMP compliance inspection application by the end of the year [2][6] - The market for traditional Chinese medicine liquid preparations, including oral liquids, has seen continuous growth, with sales exceeding 20 billion yuan in 2023 and expected to maintain stable growth in 2024 [4] - The company has established a closed-loop production system suitable for continuous production of traditional Chinese medicine, enhancing production efficiency and flexibility [6] Company Developments - The new production line will increase the company's total liquid preparation production capacity to 240 million bottles annually, with a maximum daily capacity of 800,000 bottles [2] - Key equipment upgrades include a new water bath sterilizer with a 42.8% increase in capacity and an AI-driven automatic light inspection machine for optimized detection parameters [6] - The company is advancing its "smart production line" initiative, focusing on data integration across the entire supply chain from planting to production and consumption [6] Market Trends - The main categories driving the market include medications for respiratory diseases, tonics for energy and blood, and digestive system diseases [4] - Tongrentang Technology's oral liquid products, such as Shenmai Drink and Children's Cough Syrup, are gaining traction due to their quick efficacy, precise dosing, and ease of use, aligning with modern consumer demands [4]

同仁堂科技相关负责人介绍说，液体制剂首期建设项目中，企业创建了适于中药制造连续生产的闭环生 产体系，整合提取、配液、灌装等9个生产环节，实现了不断线生产。在此基础上，新增生产线关键设 备也进行了升级——新型水浴式灭菌柜单柜产能提升42.8%，全自动灯检机引入AI深度学习技术，实现 检测参数自优化。 北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技"）液体制剂产能布局实现重要进展。据悉， 其旗下科技唐山公司新增液体制剂（口服液）连线已完成设备与工艺验证，预计年内向药品监管部门提 交GMP符合性检查申报。该产线投产后，公司将拥有4条液体制剂连线，单日最大产能达80万支，年设 计总产能突破2.4亿支，为中成药液体制剂市场供给提供有力支撑。 米内网数据显示，包含口服液在内的中成药溶液剂在中国零售药店终端市场规模持续增长，2023年销售 额已突破200亿元，2024年保持稳定增长。呼吸系统疾病用药、补气补血类用药及消化系统疾病用药成 为市场主力品类。同仁堂科技旗下生脉饮、儿童咳液、安神健脑液等口服液品种，凭借其"起效快、剂 量准、易服用"的剂型优势，契合现代消费需求，已成为公司业绩增长的重要驱动力。 生产管理方面， ...